DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8e40c6/global_biopharma_o) has announced the addition of the "Global Biopharma Outlook 2012 - India Pharma" report to their offering.
Global Biopharma Outlook 2012: India Pharma
Growth Drivers for India Pharma: Para IV and Domestic market
Domestic Formulations -
- Regulatory Reforms on manufacturing, marketing and distribution
- Impact of regulatory reforms on consolidation
- Recent reforms and its impact
- Draft Drug Pricing Policy - Analysis and Impact
Para IV Opportunity -
- Expected New Generics in 2012, 2013 and 2014
- Indian companies' comprehensive list of likely 180-day exclusivities.
- Likely forfeiture of exclusivities
Key Topics Covered:
Global Biopharma Outlook 2012: India Pharma
Macro Analysis
Investment Conclusions
CY12 Investment Drivers & Criteria
Domestic Formulations: Reforms & Consolidation continue
Recent reforms (GMP+GLP) drive market growth by improving manufacturing practices
Draft of drug pricing policy- Neutral to positive for the industry
Para IV led growth- Indian companies poised to make the most
Companies Mentioned:
- Aurobindo
- Biocon
- Cadila
- Cipla
- Dishman
- Dr Reddy's
- Ipca
- Lupin
- Ranbaxy
- Sun Pharma
For more information visit http://www.researchandmarkets.com/research/8e40c6/global_biopharma_o